Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | TTK | P33981 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036637 | 0.93 | BACE1 (0.43) | BACE1AXLMERTKTTKMAPT | |
| SCHEMBL3036644 | 0.93 | BACE1 (0.43) | BACE1AXLMERTKTTKMAPT | |
| SCHEMBL3038261 | 0.91 | TTK (0.42) | BACE1AXLMERTKTTKMAPT | |
| SCHEMBL3038265 | 0.91 | TTK (0.42) | BACE1AXLMERTKTTKMAPT | |
| SCHEMBL2946038 | 0.84 | AXL (0.47) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL2946205 | 0.81 | MERTK (0.48) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL3703315 | 0.81 | AXL (0.50) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL4764869 | 0.81 | TTK (0.54) | TTK | |
| SCHEMBL2946536 | 0.81 | AXL (0.44) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL4766002 | 0.80 | TTK (0.47) | AXLMERTKTTKADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | BACE1 1396/4885AXL 2976/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.